LONDON, UK / ACCESSWIRE / October 4, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on pSivida Corp. (NASDAQ: PSDV), which can be viewed by registering at http://protraderdaily.com/optin/?symbol=PSDV, following the Company's announcement of its fourth quarter and fiscal year 2017 financial results on September 11, 2017. The developer of sustained release drug products and technologies exceeded revenue expectations. Our daily stock reports are accessible for free, and with those to look forward today you also will be signing up for a complimentary member's account at:
At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on PSDV. With the links below you can directly download the report of your stock of interest free of charge at:
For the fourth quarter ended June 30, 2017, pSivida's revenue totaled $701,000 compared to $304,000 for Q4 FY16. The Company's revenue beat analysts' estimates of $0.48 million.
pSivida generated revenue of $461,000 through collaborative research and development in the reported quarter compared to $26,000 in the year earlier same quarter. The Company recorded royalty income of $240,000 in Q4 FY17 compared to $278,000 in Q4 FY16.
pSivida's revenue was $7.5 million for FY17 compared to $1.6 million for FY16. The y-o-y growth was primarily attributable to the $5.6 million of revenue recognized in Q2 FY17, upon termination of the Pfizer agreement.
During Q4 FY17, pSivida's operating expenses totaled $6.84 million compared to $6.76 million in Q4 FY16. The Company's net loss was $6.1 million, or $0.16 per share, for the reported quarter compared to a net loss of $6.4 million, or $0.19 per share, for the prior year's corresponding quarter, and met Wall Street's estimates for a loss of $0.16 per share.
For FY17, pSivida's net loss totaled $18.5 million, or $0.52 per share, compared to a net loss of $21.5 million, or $0.68 per share, for the fiscal year ended June 30, 2016.
Operational Highlights Fiscal Year 2017
On June 13, 2017, pSivida reported that data from the second Phase-3 trial of Durasert™ three-year treatment for posterior segment uveitis achieved its primary endpoint. The results demonstrated a significant reduction in the recurrence of posterior segment uveitis through six months; 21.8% of Durasert-treated patients had a recurrence compared to 53.8% of patients in the sham group.
The Company successfully completed a pre-NDA meeting with the US Food and Drug Administration (FDA) for Durasert three-year uveitis that included FDA's agreement with pSivida's proposed overall clinical data package. The Company expects to file the NDA in late December or early January.
On July 10, 2017, pSivida amended the existing collaboration agreement with Alimera Sciences, Inc. (NASDAQ:ALIM) for ILUVIEN® to change the payment terms to a net sales royalty paid to pSivida, resulting in improved financial terms for the Company, and to grant regulatory and commercial rights to Durasert three-year uveitis in Europe, the Middle-East, and Africa (EMEA).
Hospital for Special Surgery (HSS) completed enrollment in an investigator-sponsored Phase-1 study to evaluate safety and the effect on pain and function of a combination product including Durasert technology providing sustained delivery of dexamethasone for the management of osteoarthritic knees.
During Q4 FY17, the Company issued approximately 3.7 million shares of common stock for gross proceeds of $6.4 million through utilization of its existing at-the-market (ATM) equity offering program. At June 30, 2017, pSivida's cash and cash equivalents totaled $16.9 million. During the reported quarter, net cash used in operations totaled approximately $4.5 million.
On Tuesday, October 03, 2017, pSivida's stock closed the trading session flat at $1.20. A total volume of 384.25 thousand shares were exchanged during the session. The stock currently has a market cap of $46.81 million.
Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (917) 341.4653
Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Pro-Trader Daily